WUXI BIO sells overseas Assets, but not because of the biosecurity legislation.
By adjusting the Assets, WUXI BIO has released more space and will further increase its overseas investments.
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
WUXI BIO has once again divested overseas Assets! Merck takes over WUXI BIO's Ireland vaccine factory for 0.5 billion USD | Quick read announcement.
① WUXI BIO announced today that it will sell the Ireland vaccine factory to Merck for 0.5 billion USD; ② this vaccine factory was originally built to undertake Merck's vaccine contract manufacturing business; ③ not long ago, WUXI APPTEC also divested its WuXi ATU business in the USA and United Kingdom.
Not just a simple "split": The multifaceted considerations behind the sale of WUXI APPTEC's CGT Business.
In an era where Globalization and protectionism coexist, the rapid iteration of cutting-edge technologies, alongside multiple constraints from policies and capital, poses unprecedented challenges for pharmaceutical innovation companies.
Selling ATU's USA and United Kingdom Business, the strategy behind WUXI APPTEC.
There is gain in loss.
WUXI APPTEC will transfer the WuXi ATU Business to a USA Fund. Is the "optimal solution" for the "gray rhino" of the Biological Safety Act?
① This evening, WUXI APPTEC announced that it will transfer its WuXi ATU Business in the USA and United Kingdom to the USA Private Equity Fund Altaris in exchange for Cash.; ② In the first three quarters, WuXi ATU achieved revenue of 0.853 billion, accounting for only about 3% of the total revenue for the first three quarters.; ③ After the transfer of this Business, the accusations and suspicions related to its gene business may be cleared under the Biosecurity Act.